Moderna: Cancer Vaccine Could Top Keytruda
Moderna: Cancer Vaccine Could Top Keytruda
Moderna: Cancer Vaccine Could Top Keytruda
Key points
اہم نکات
मुख्य बातें
- Moderna's personalised cancer vaccine cut the risk of melanoma returning or killing patients by 42%, and its chief executive says it could one day outsell Keytruda, the world's biggest cancer drug.
- The mRNA vaccine, intismeran, is made for each patient from their own tumour and given alongside Merck's Keytruda; in a Phase III trial of more than 1,100 high-risk melanoma patients it also cut the risk of the cancer spreading by 38%.
- Chief executive Stephane Bancel told the Financial Times pharma summit on November 10 that the treatment will be tried everywhere Keytruda works, including lung, bladder and pancreatic cancers.
- Moderna's personalised cancer vaccine cut the risk of melanoma returning or killing patients by 42%, and its chief executive says it could one day outsell Keytruda, the world's biggest cancer drug.
- The mRNA vaccine, intismeran, is made for each patient from their own tumour and given alongside Merck's Keytruda; in a Phase III trial of more than 1,100 high-risk melanoma patients it also cut the risk of the cancer spreading by 38%.
- Chief executive Stephane Bancel told the Financial Times pharma summit on November 10 that the treatment will be tried everywhere Keytruda works, including lung, bladder and pancreatic cancers.
- Moderna's personalised cancer vaccine cut the risk of melanoma returning or killing patients by 42%, and its chief executive says it could one day outsell Keytruda, the world's biggest cancer drug.
- The mRNA vaccine, intismeran, is made for each patient from their own tumour and given alongside Merck's Keytruda; in a Phase III trial of more than 1,100 high-risk melanoma patients it also cut the risk of the cancer spreading by 38%.
- Chief executive Stephane Bancel told the Financial Times pharma summit on November 10 that the treatment will be tried everywhere Keytruda works, including lung, bladder and pancreatic cancers.
Moderna's personalised cancer vaccine cut the risk of melanoma returning or killing patients by 42%, and its chief executive says it could one day outsell Keytruda, the world's biggest cancer drug. The mRNA vaccine, intismeran, is made for each patient from their own tumour and given alongside Merck's Keytruda; in a Phase III trial of more than 1,100 high-risk melanoma patients it also cut the risk of the cancer spreading by 38%. Chief executive Stephane Bancel told the Financial Times pharma summit on November 10 that the treatment will be tried everywhere Keytruda works, including lung, bladder and pancreatic cancers. Moderna hopes to launch commercially in 2027 if regulators approve it, after shares in the company rose sharply on the trial results.
Moderna's personalised cancer vaccine cut the risk of melanoma returning or killing patients by 42%, and its chief executive says it could one day outsell Keytruda, the world's biggest cancer drug. The mRNA vaccine, intismeran, is made for each patient from their own tumour and given alongside Merck's Keytruda; in a Phase III trial of more than 1,100 high-risk melanoma patients it also cut the risk of the cancer spreading by 38%. Chief executive Stephane Bancel told the Financial Times pharma summit on November 10 that the treatment will be tried everywhere Keytruda works, including lung, bladder and pancreatic cancers. Moderna hopes to launch commercially in 2027 if regulators approve it, after shares in the company rose sharply on the trial results.
Moderna's personalised cancer vaccine cut the risk of melanoma returning or killing patients by 42%, and its chief executive says it could one day outsell Keytruda, the world's biggest cancer drug. The mRNA vaccine, intismeran, is made for each patient from their own tumour and given alongside Merck's Keytruda; in a Phase III trial of more than 1,100 high-risk melanoma patients it also cut the risk of the cancer spreading by 38%. Chief executive Stephane Bancel told the Financial Times pharma summit on November 10 that the treatment will be tried everywhere Keytruda works, including lung, bladder and pancreatic cancers. Moderna hopes to launch commercially in 2027 if regulators approve it, after shares in the company rose sharply on the trial results.
Most read
سب سے زیادہ پڑھی گئی
सबसे ज़्यादा पढ़ी गई
- Loading...
Get news in your inbox
خبریں اپنے ان باکس میں حاصل کریں
खबरें अपने इनबॉक्स में पाएं
One email when new stories are published. No spam, unsubscribe anytime.
نئی خبریں شائع ہونے پر ایک ای میل۔ کوئی سپیم نہیں، کسی بھی وقت ان سبسکرائب کریں۔
नई खबरें प्रकाशित होने पर एक ईमेल। कोई स्पैम नहीं, कभी भी अनसब्सक्राइब करें।